973MO KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC - Garassino, MC; Gadgeel, SM; Speranza, G (Annals of Oncology, 2022)
et al.